Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIVE pre-HF: Empagliflozin and exercise mHealth in pre-heart failure with preserved ejection fraction
2022-002650-48Phase 2Active
- Sponsor
- University College Dublin
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF) and heart failure (HF) (2 arms), sponsored by University College Dublin. Primary endpoint: Change in left atrial volume index (LAVImax) by CMR over 6 months. Started Jan 2023; status: active.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure (HF)
Beyond the preview
Go deeper on 2022-002650-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002650-48.